The achievement of complete response (CR) after high-dose therapy/autologous stem cell transplantation (HDT/ASCT) is a surrogate for prolonged survival in multiple myeloma; however, patients who lose their CR status within 1 year of HDT/ASCT (unsustained CR) have poor prognosis. Thus, the identification of these patients is highly relevant. Here, we investigate which prognostic markers can predict unsustained CR in a series of 241 patients in CR at day ؉100 after HDT/ASCT who were enrolled in the Spanish GEM2000 (n ‫؍‬ 140) and GEM2005 < 65y (n ‫؍‬ 101) trials. Twenty-nine (12%) of the 241 patients showed unsustained CR and a dismal outcome (median overall survival 39 months). The presence of baseline high-risk cytogenetics by FISH (hazard ratio 17.3; P ‫؍‬ .002) and persis-tent minimal residual disease by multiparameter flow cytometry at day ؉100 after HDT/ASCT (hazard ratio 8.0; P ‫؍‬ .005) were the only independent factors that predicted unsustained CR. Thus, these 2 parameters may help to identify patients in CR at risk of early progression after HDT/ASCT in whom novel treatments should be investigated. (Blood.  2012;119(3):687-691) 
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Introduction
The incorporation of high-dose therapy/autologous stem cell transplantation (HDT/ASCT) and novel agents in the treatment of young patients with multiple myeloma (MM) has markedly improved the achievement of complete response (CR). 1, 2 There are now extensive data in the setting of HDT/ASCT showing that achievement of CR is associated with prolonged survival. 3 Although this is well accepted, the long-term clinical outcome of MM patients who achieve CR is still heterogeneous, 4 and 2 important observations must be made: (1) some patients who revert to a monoclonal gammopathy of undetermined significance (MGUS) stage after therapy experience similar prolonged survival as patients in CR 5 ; and (2) a small fraction of patients unexpectedly lose their CR status during the first year after HDT/ASCT and experience a dismal survival rate. 6, 7 In fact, survival of patients with unsustained CR is even poorer than for those not achieving CR. 6, 7 Herein, we sought to identify prognostic markers predictive of unsustained CR after HDT/ASCT.
Methods
The study included 241 MM patients diagnosed according to International Myeloma Working Group criteria. 8 Patients were included in 2 consecutive PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) trials: GEM2000 (VBMCP [vincristine, carmustine, melphalan, cyclophosphamide, and prednisone]/VBAD [vincristine, carmustine, doxorubicin, and dexamethasone] followed by HDT/ASCT and 2 years of maintenance with interferon and prednisone; n ϭ 140) and GEM2005 Ͻ 65y (randomized induction with the same chemotherapy plus bortezomib in the last 2 cycles or thalidomide/dexamethasone or bortezomib/thalidomide/dexamethasone followed by HDT/ASCT, and 3 years of maintenance with interferon-␣2b or thalidomide or thalidomide/bortezomib; n ϭ 101). All case subjects were in CR at day ϩ100 after HDT/ASCT, defined as absence of the original M component by immunofixation and Ͻ 5% plasma cells (PCs) in BM. 9 Patients showing progressive disease within the first year after HDT/ASCT Submitted July 26, 2011; accepted November 18, 2011. Prepublished online as Blood First Edition paper, November 29, 2011; DOI 10.1182/blood-2011-07-370460.
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were classified as having unsustained CR. Median follow-up of the entire series was 49 months.
Erythrocyte-lysed BM samples from 241 patients were immunophenotyped by use of a 4-color (CD38/CD56/CD19/CD45, CD38/CD27/CD45/ CD28, and ␤2-microglobulin/CD81/CD38/CD117) direct immunofluorescence technique. The phenotypic aberrancies detected at diagnosis allowed normal PCs and myelomatous PCs to be discriminated, as described elsewhere, 10 and were used as patient-specific probes for minimal residual disease (MRD) assessment at day ϩ100 after HDT/ASCT. 11 Patients were defined as being in immunophenotypic CR 12 when myelomatous PCs were undetectable by multiparameter flow cytometry (MFC) at a sensitivity of Յ 10 Ϫ4 to 10 Ϫ5 .
FISH was performed at baseline in immunomagnetic-enriched PCs from 110 case subjects. Patients harboring a t(4;14), t(14;16), or del(17p) were classified as having high-risk disease and all other cases as being at standard risk, according to International Myeloma Working Group guidelines. 13 Conventional cytogenetics were not part of the GEM2000 and GEM2005 Ͻ 65y workload; therefore, abnormalities on chromosome 1 or 13 were not a criterion to define high-risk patients. Samples were collected after informed consent was obtained in accordance with the Declaration of Helsinki and with approval from the ethics committees of all participating institutions.
The 2 and Mann-Whitney U tests were used to estimate statistically significant differences. Survival curves were plotted by the Kaplan-Meier method, with differences assessed with the log-rank test. For multivariate analysis, stepwise Cox proportional hazard and logistic regressions were performed with SPSS Version 15.0 software (SPSS Inc).
Results and discussion
Time to progression (TTP; median 71 months) and overall survival (OS; 71% at 5 years) of patients in CR were longer than those in less than CR at day ϩ100 after HDT/ASCT (TTP: median 47 months, P Ͻ .001; Figure 1A ; OS: 60% at 5 years, P Ͻ .001; Figure 1B ). Nevertheless, the baseline characteristics of the 241 patients in CR did not differ greatly from those not achieving CR at day ϩ100 after HDT/ASCT (data not shown).
We first investigated which of the most relevant disease characteristics had prognostic influence in patients in CR at day ϩ100 after HDT/ASCT. In the present study cohort, some of the markers with consistent influence in unselected myeloma populations, such as patient age, International Staging System disease stage, serum albumin and ␤ 2 -microglobulin, BM PC burden, percentage of PCs in S phase, and the achievement of CR after induction, were not of significant predictive value (Table 1 ). In addition, the type of induction was not of significant prognostic value in this selected population of patients in CR at day ϩ100 after HDT/ASCT. In contrast, significant differences according to the type of maintenance therapy (interferon/prednisone versus interferon-␣2b versus thalidomide versus thalidomide/bortezomib) were noted for TTP (74% vs 60% vs 87% vs 84% at 3 years, respectively; P ϭ .006), as was a trend for OS (89% vs 87% vs 94% vs 100% at 3 years, respectively; P ϭ .08), whereas the presence of baseline anemia was a significant prognostic marker for OS (P ϭ .01). With regard to cytogenetics, 16% of CR patients were considered to have high-risk disease at presentation and showed a significantly inferior TTP (3 years, 40% vs 80%; P Ͻ .001) and borderline OS (3 years, 73% vs 96%; P ϭ .07) compared with case subjects with standard risk. In addition, MFC immunophenotyping showed persistent MRD in 87 (36%) of the 241 CR patients, and the failure to achieve an immunophenotypic CR at day ϩ100 after HDT/ASCT resulted in significantly inferior TTP (3 years, 58% versus 86%; P Ͻ .001) and OS (3 years, 80% vs 90%; P ϭ .001).
In the multivariate analysis, the best combination of independent predictive parameters for TTP was immunophenotypic CR status (P Ͻ .001; hazard ratio [HR] 7.7) and FISH cytogenetics (P Ͻ .001; HR ϭ 6.4); in turn, for OS, immunophenotypic CR status (P ϭ .003; HR ϭ 6.6), FISH cytogenetics (P ϭ .03; HR ϭ 4.3), and age Ն 60 years (P ϭ .03; HR ϭ 3.5) were selected.
Results with novel induction regimens showed similar CR rates for high-and standard-risk cytogenetic cases, [14] [15] [16] [17] although the former population usually shows shorter progression-free survival, [14] [15] [16] [17] [18] which reinforces the need for additional tools for early identification of unsustained CR. In line with previous observations, 10, 11, [19] [20] [21] [22] we have shown that when highly sensitive techniques are used, persistent MRD is still detectable in an important fraction of patients in CR after HDT/ASCT. We further explored the clinical impact of the immunophenotypic CR in the context of standardrisk and high-risk disease. As expected, the best prognosis was for patients with both standard-risk cytogenetics and achievement of an immunophenotypic CR (3 years: TTP 94%, OS 100%), whereas the worst outcome occurred in cases with both high-risk disease and persistent MRD (3 years: TTP 0%, OS 32%; P Ͻ .001). The 2 other categories had an intermediate prognosis, with no significant differences between the subgroup with high-risk cytogenetics who achieved an immunophenotypic CR (3 years: TTP 69%, OS 100%) and patients with standard-risk disease but who failed to achieve an immunophenotypic CR after HDT/ASCT (3 years: TTP 57%, OS 90%; P ϭ .5). After this analysis of the overall population of patients in CR, we investigated the parameters that could help to identify patients in CR at risk of early relapse (Յ 1 year) after HDT/ASCT. Of the 241 patients, 29 (12%) progressed within 1 year after HDT/ASCT (unsustained CR), and this subgroup was investigated further. In agreement with previous observations, 6, 7 patients in the present series with unsustained CR showed a dismal outcome, with a median OS of only 39 months (P Ͻ .001; Figure 1B ). Information on the salvage therapy of these 29 patients is included in supplemental Table 1 (available on the Blood Web site; see the Supplemental Materials link at the top of the online article). Patients with unsustained CR had a significantly higher incidence of anemia at baseline (50% vs 26%, P ϭ .008), advanced International Staging System stage II or III (85% vs 56%, P ϭ .005), high-risk cytogenetics (42% vs 10%, P ϭ .002), and persistent MRD by MFC (66% vs 32%, P ϭ .001) compared with the remaining cases. In addition, patients scheduled to receive interferon-␣2b without prednisone showed a significantly increased frequency of unsustained CR versus those scheduled to receive other regimens (26% vs 9%, P ϭ .01). Previous observations 23 have suggested that patients who demonstrate an early response to therapy may be associated with an aggressive MM and poor prognosis; however, this was not observed in the present study, because patients with unsustained CR showed a trend toward lower CR rates before HDT/ASCT (33% vs 54%; P ϭ .061). On multivariate analysis, only the pattern of cytogenetic abnormalities (P ϭ .002, HR ϭ 17.3) and the immunophenotypic CR status at day ϩ100 after HDT/ASCT (P ϭ .005, HR ϭ 8.0) emerged as independent predictive markers for unsustained CR. Of note, when the 3-year cutoff previously reported by the Arkansas group 6,7 was used to define unsustained CR after HDT/ASCT, this subgroup of patients (n ϭ 64; 27%) showed a poor outcome, albeit better than that of patients who lost their CR status within the first year (median OS of 58 vs 39 months; P ϭ .03). On the basis of these 2 variables, we established a predictive index by assigning 1 point for each adverse factor. Accordingly, 3 risk groups of patients in CR after HDT/ASCT were defined, with significantly (P Ͻ .001) different rates of disease progression ( Figure 1C ) within the first year after HDT/ASCT for patients with none, 1, or both of the risk factors (median TTP of 83, 26, and 6 months, respectively). This predictive index according to FISH cytogenetics and MRD status by MFC also had a clear effect on OS of patients in CR at day ϩ100 after ASCT ( Figure 1D) .
The results of the present study show that the baseline evaluation of cytogenetic abnormalities combined with response assessment by MRD can discriminate a subset of CR patients with a dismal outcome who should be candidates for novel treatment strategies after HDT/ASCT.
